| Analysis | Metabolite Name | Measured Value | Units | Genotype | Treatment |
|---|---|---|---|---|---|
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | PRDX1 KO | Etop-0h | |
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | PRDX1 KO | Etop-24h | |
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | PRDX1 KO | Etop-8h | |
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | PRDX1 KO | Untreated | |
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | WT | Etop-0h | |
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | WT | Etop-24h | |
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | WT | Etop-8h | |
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | WT | Noco-18h | |
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | WT | Noco-23h | |
| Normal phase NEGATIVE ION MODE | Pyridoxamine | au | WT | Untreated |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|